Skip to main content
logo
Adaptimmune Therapeutics plc (ADAPY)
OTCMKTS · Delayed Price · Currency is USD
0.0350
+0.0030 (9.38%)
At close: Oct 19, 2026

Adaptimmune Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
5.925.92-60.2827.156.15
Revenue Growth
-96.62%--122.05%341.50%55.36%
Gross Profit
5.925.92--66.23-100.58-104.94
Operating Income
-64.12-64.12-172.54-130.69-163.97-162.25
Net Income
25.2125.21-71.88-113.87-165.46-158.09
Earnings Per Share
0.080.08-0.30-0.57-1.03-1.02
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
25.9525.95151.61146.94204.61369.58
Total Debt
14.0814.0874.2925.2423.0825.47
Net Cash (Debt)
11.8711.8777.32121.7181.53344.11
Net Cash Growth
-89.36%-84.65%-36.47%-32.96%-47.25%-0.11%
Net Cash Per Share
0.040.040.310.611.132.21

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-121.91-121.91-69.12-140.88-141.7710.73
Capital Expenditures
-0.39-0.39-0.89-4.68-29.5-8.57
Free Cash Flow
-122.3-122.3-70-145.56-171.272.16
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
100.00%100.00%--109.86%--
Operating Margin
-1082.41%-1082.41%--216.81%-603.97%-2638.58%
Pretax Margin
-1316.78%-1316.78%--186.68%-600.26%-2558.12%
Profit Margin
425.49%425.49%--188.90%-609.46%-2570.99%
FCF Margin
-2064.40%-2064.40%--241.47%-630.86%35.05%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingOct '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
0.370.27----
P/FCF Ratio
-----271.82
PS Ratio
1.571.16-2.998.8195.26